SCHEDULE: YD Bio Ltd: Ethan Shen Boosts Stake to 77.1%

Ethan Shen and his affiliated entities have reported beneficial ownership of 77.1% of YD Bio Ltd's ordinary shares as of September 30, 2025.

Summary

• Ethan Shen, through YD Biopharma Holding Limited and EG Biomed Limited, beneficially owns 54,345,011 ordinary shares of YD Bio Ltd.
• This ownership represents 77.1% of the total 70,521,359 ordinary shares outstanding as of November 17, 2025.
• YD Biopharma Holding Limited holds 43,120,858 shares, accounting for 61.1% of the class.
• EG Biomed Limited holds 11,224,153 shares, accounting for 15.9% of the class.
• Dr. Shen is the beneficial owner of all equity interests in YD Biopharma Holding Limited and wholly owns EG Biomed Limited.
• The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's operational or financial performance.

Positives

• High insider ownership by Ethan Shen (77.1%) indicates strong alignment of interests between the major shareholder and the company's performance.
• Consolidated control by a single individual/group can lead to more decisive strategic execution and potentially streamlined decision-making.

Negatives

• The extremely high concentration of ownership (77.1%) by a single individual/group could limit the liquidity of the company's shares for other investors.
• Minority shareholders may have limited influence over corporate decisions due to the dominant ownership stake held by Ethan Shen and his entities.

Risks

• The filing does not explicitly detail specific operational or financial risks. However, the highly concentrated ownership structure (77.1% by Ethan Shen and his entities) inherently presents a risk of limited minority shareholder influence and potential governance challenges if interests diverge.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The high concentration of ownership by Ethan Shen and his entities (77.1%) means that minority shareholders will have limited voting power and influence over corporate decisions. This could also potentially affect stock liquidity.
• Management: Ethan Shen, as the beneficial owner of the majority stake, has significant control over the company's strategic direction and management appointments.

Key Dates

Keywords

YD Bio Ltd, Ethan Shen, Beneficial Ownership, Schedule 13G, Ordinary Shares, YD Biopharma Holding Limited, EG Biomed Limited, Shareholder, Ownership Stake, SEC Filing